nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—BGLAP—osteoporosis	0.738	1	CbGaD
Phylloquinone—BGLAP—forelimb zeugopod—osteoporosis	0.0228	0.193	CbGeAlD
Phylloquinone—BGLAP—mandible—osteoporosis	0.0225	0.191	CbGeAlD
Phylloquinone—BGLAP—jaw skeleton—osteoporosis	0.0192	0.162	CbGeAlD
Phylloquinone—BGLAP—Osteoblast Signaling—IBSP—osteoporosis	0.0156	0.192	CbGpPWpGaD
Phylloquinone—BGLAP—periosteum—osteoporosis	0.0145	0.123	CbGeAlD
Phylloquinone—BGLAP—Osteoblast Signaling—PTH1R—osteoporosis	0.0141	0.174	CbGpPWpGaD
Phylloquinone—BGLAP—vertebral column—osteoporosis	0.012	0.102	CbGeAlD
Phylloquinone—BGLAP—skull—osteoporosis	0.0119	0.101	CbGeAlD
Phylloquinone—BGLAP—parathyroid gland—osteoporosis	0.0116	0.0984	CbGeAlD
Phylloquinone—BGLAP—Osteoblast Signaling—TNFSF11—osteoporosis	0.00777	0.0957	CbGpPWpGaD
Phylloquinone—BGLAP—Osteoblast Signaling—PTH—osteoporosis	0.00742	0.0913	CbGpPWpGaD
Phylloquinone—BGLAP—Osteoblast Signaling—TNFRSF11B—osteoporosis	0.00723	0.0889	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—IBSP—osteoporosis	0.00625	0.0768	CbGpPWpGaD
Phylloquinone—BGLAP—Osteoblast Signaling—COL1A1—osteoporosis	0.00575	0.0708	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—COL1A2—osteoporosis	0.00344	0.0423	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—NFATC1—osteoporosis	0.00327	0.0402	CbGpPWpGaD
Phylloquinone—Necrosis—Calcium Acetate—osteoporosis	0.00319	0.051	CcSEcCtD
Phylloquinone—GGCX—uterus—osteoporosis	0.00193	0.0164	CbGeAlD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—NFATC1—osteoporosis	0.00173	0.0213	CbGpPWpGaD
Phylloquinone—BGLAP—bone marrow—osteoporosis	0.00168	0.0142	CbGeAlD
Phylloquinone—Injection site pain—Ibandronate—osteoporosis	0.00167	0.0267	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—KL—osteoporosis	0.00167	0.0205	CbGpPWpGaD
Phylloquinone—Inflammation—Estropipate—osteoporosis	0.00147	0.0234	CcSEcCtD
Phylloquinone—Inflammation—Ibandronate—osteoporosis	0.00141	0.0225	CcSEcCtD
Phylloquinone—Injection site reaction—Ibandronate—osteoporosis	0.00136	0.0217	CcSEcCtD
Phylloquinone—Cyanosis—Conjugated Estrogens—osteoporosis	0.00133	0.0212	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—SPP1—osteoporosis	0.00126	0.0156	CbGpPWpGaD
Phylloquinone—Necrosis—Conjugated Estrogens—osteoporosis	0.0012	0.0191	CcSEcCtD
Phylloquinone—Inflammation—Risedronate—osteoporosis	0.00116	0.0185	CcSEcCtD
Phylloquinone—Swelling—Ibandronate—osteoporosis	0.00112	0.0179	CcSEcCtD
Phylloquinone—Inflammation—Pamidronate—osteoporosis	0.0011	0.0176	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Estropipate—osteoporosis	0.00107	0.017	CcSEcCtD
Phylloquinone—Inflammation—Zoledronate—osteoporosis	0.00101	0.0161	CcSEcCtD
Phylloquinone—Injection site reaction—Zoledronate—osteoporosis	0.000971	0.0155	CcSEcCtD
Phylloquinone—Inflammation—Conjugated Estrogens—osteoporosis	0.00097	0.0155	CcSEcCtD
Phylloquinone—Phlebitis—Pamidronate—osteoporosis	0.000901	0.0144	CcSEcCtD
Phylloquinone—Swelling—Pamidronate—osteoporosis	0.00088	0.014	CcSEcCtD
Phylloquinone—Hypotension—Calcium Acetate—osteoporosis	0.000836	0.0133	CcSEcCtD
Phylloquinone—Swelling—Zoledronate—osteoporosis	0.000804	0.0128	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Pamidronate—osteoporosis	0.000802	0.0128	CcSEcCtD
Phylloquinone—Phlebitis—Conjugated Estrogens—osteoporosis	0.000793	0.0127	CcSEcCtD
Phylloquinone—Inflammation—Estradiol—osteoporosis	0.000776	0.0124	CcSEcCtD
Phylloquinone—Swelling—Conjugated Estrogens—osteoporosis	0.000774	0.0124	CcSEcCtD
Phylloquinone—Pain—Calcium Acetate—osteoporosis	0.000765	0.0122	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CCT2—osteoporosis	0.000755	0.00929	CbGpPWpGaD
Phylloquinone—Sweating—Raloxifene—osteoporosis	0.00074	0.0118	CcSEcCtD
Phylloquinone—Sweating—Ibandronate—osteoporosis	0.000732	0.0117	CcSEcCtD
Phylloquinone—Erythema—Etidronic acid—osteoporosis	0.00072	0.0115	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Conjugated Estrogens—osteoporosis	0.000706	0.0113	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—POMC—osteoporosis	0.000688	0.00847	CbGpPWpGaD
Phylloquinone—Pain—Ergocalciferol—osteoporosis	0.000676	0.0108	CcSEcCtD
Phylloquinone—Hypersensitivity—Calcium Acetate—osteoporosis	0.000659	0.0105	CcSEcCtD
Phylloquinone—Sweating increased—Pamidronate—osteoporosis	0.000654	0.0104	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—TGFB1—osteoporosis	0.000653	0.00804	CbGpPWpGaD
Phylloquinone—Immune system disorder—Estropipate—osteoporosis	0.000646	0.0103	CcSEcCtD
Phylloquinone—Flushing—Raloxifene—osteoporosis	0.000643	0.0103	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—TUBA1B—osteoporosis	0.000642	0.0079	CbGpPWpGaD
Phylloquinone—Phlebitis—Estradiol—osteoporosis	0.000635	0.0101	CcSEcCtD
Phylloquinone—Erythema—Estropipate—osteoporosis	0.000623	0.00993	CcSEcCtD
Phylloquinone—Swelling—Estradiol—osteoporosis	0.00062	0.00989	CcSEcCtD
Phylloquinone—Immune system disorder—Ibandronate—osteoporosis	0.000619	0.00988	CcSEcCtD
Phylloquinone—Erythema—Alendronate—osteoporosis	0.000613	0.00978	CcSEcCtD
Phylloquinone—Sweating increased—Zoledronate—osteoporosis	0.000597	0.00953	CcSEcCtD
Phylloquinone—Erythema—Ibandronate—osteoporosis	0.000597	0.00952	CcSEcCtD
Phylloquinone—Dizziness—Calcium Acetate—osteoporosis	0.000592	0.00944	CcSEcCtD
Phylloquinone—Erythema—Calcitriol—osteoporosis	0.000584	0.00932	CcSEcCtD
Phylloquinone—Sweating increased—Conjugated Estrogens—osteoporosis	0.000575	0.00918	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—osteoporosis	0.000565	0.00696	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Estradiol—osteoporosis	0.000565	0.00901	CcSEcCtD
Phylloquinone—Immune system disorder—Ethinyl Estradiol—osteoporosis	0.000524	0.00835	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—RPL24—osteoporosis	0.000513	0.00632	CbGpPWpGaD
Phylloquinone—Immune system disorder—Risedronate—osteoporosis	0.00051	0.00814	CcSEcCtD
Phylloquinone—Anaphylactic shock—Estropipate—osteoporosis	0.000508	0.00811	CcSEcCtD
Phylloquinone—Flushing—Pamidronate—osteoporosis	0.000499	0.00796	CcSEcCtD
Phylloquinone—Anaphylactic shock—Ibandronate—osteoporosis	0.000487	0.00777	CcSEcCtD
Phylloquinone—Immune system disorder—Pamidronate—osteoporosis	0.000485	0.00774	CcSEcCtD
Phylloquinone—Anaphylactic shock—Calcitriol—osteoporosis	0.000477	0.00761	CcSEcCtD
Phylloquinone—Hyperhidrosis—Raloxifene—osteoporosis	0.000476	0.00759	CcSEcCtD
Phylloquinone—Hyperhidrosis—Ibandronate—osteoporosis	0.000471	0.00751	CcSEcCtD
Phylloquinone—Erythema—Pamidronate—osteoporosis	0.000468	0.00746	CcSEcCtD
Phylloquinone—Sweating increased—Estradiol—osteoporosis	0.00046	0.00734	CcSEcCtD
Phylloquinone—Flushing—Zoledronate—osteoporosis	0.000455	0.00727	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—TLN1—osteoporosis	0.000451	0.00555	CbGpPWpGaD
Phylloquinone—Immune system disorder—Zoledronate—osteoporosis	0.000443	0.00707	CcSEcCtD
Phylloquinone—Pain—Estropipate—osteoporosis	0.000434	0.00693	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—REN—osteoporosis	0.000434	0.00534	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Etidronic acid—osteoporosis	0.000433	0.0069	CcSEcCtD
Phylloquinone—Pain—Alendronate—osteoporosis	0.000428	0.00683	CcSEcCtD
Phylloquinone—Erythema—Zoledronate—osteoporosis	0.000427	0.00682	CcSEcCtD
Phylloquinone—Immune system disorder—Conjugated Estrogens—osteoporosis	0.000427	0.00681	CcSEcCtD
Phylloquinone—Pain—Raloxifene—osteoporosis	0.000421	0.00671	CcSEcCtD
Phylloquinone—Pain—Ibandronate—osteoporosis	0.000417	0.00665	CcSEcCtD
Phylloquinone—Erythema—Conjugated Estrogens—osteoporosis	0.000411	0.00656	CcSEcCtD
Phylloquinone—Pain—Calcitriol—osteoporosis	0.000408	0.00651	CcSEcCtD
Phylloquinone—Anaphylactic shock—Pamidronate—osteoporosis	0.000382	0.00609	CcSEcCtD
Phylloquinone—Hypersensitivity—Estropipate—osteoporosis	0.000374	0.00597	CcSEcCtD
Phylloquinone—Hyperhidrosis—Pamidronate—osteoporosis	0.000369	0.00589	CcSEcCtD
Phylloquinone—Hypersensitivity—Alendronate—osteoporosis	0.000369	0.00588	CcSEcCtD
Phylloquinone—Hypersensitivity—Ibandronate—osteoporosis	0.000359	0.00573	CcSEcCtD
Phylloquinone—Dyspnoea—Risedronate—osteoporosis	0.000358	0.00571	CcSEcCtD
Phylloquinone—Hypotension—Pamidronate—osteoporosis	0.000357	0.00569	CcSEcCtD
Phylloquinone—Hypersensitivity—Calcitriol—osteoporosis	0.000351	0.00561	CcSEcCtD
Phylloquinone—Flushing—Estradiol—osteoporosis	0.000351	0.0056	CcSEcCtD
Phylloquinone—Anaphylactic shock—Zoledronate—osteoporosis	0.000349	0.00556	CcSEcCtD
Phylloquinone—Pain—Risedronate—osteoporosis	0.000343	0.00548	CcSEcCtD
Phylloquinone—Immune system disorder—Estradiol—osteoporosis	0.000342	0.00545	CcSEcCtD
Phylloquinone—Dyspnoea—Pamidronate—osteoporosis	0.00034	0.00543	CcSEcCtD
Phylloquinone—Hyperhidrosis—Zoledronate—osteoporosis	0.000337	0.00538	CcSEcCtD
Phylloquinone—Dizziness—Estropipate—osteoporosis	0.000336	0.00536	CcSEcCtD
Phylloquinone—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000336	0.00536	CcSEcCtD
Phylloquinone—Dizziness—Alendronate—osteoporosis	0.000331	0.00528	CcSEcCtD
Phylloquinone—Erythema—Estradiol—osteoporosis	0.000329	0.00525	CcSEcCtD
Phylloquinone—Pain—Pamidronate—osteoporosis	0.000326	0.00521	CcSEcCtD
Phylloquinone—Hypotension—Zoledronate—osteoporosis	0.000326	0.0052	CcSEcCtD
Phylloquinone—Dizziness—Raloxifene—osteoporosis	0.000325	0.00519	CcSEcCtD
Phylloquinone—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000325	0.00518	CcSEcCtD
Phylloquinone—Dizziness—Ibandronate—osteoporosis	0.000322	0.00514	CcSEcCtD
Phylloquinone—Hypotension—Conjugated Estrogens—osteoporosis	0.000314	0.00501	CcSEcCtD
Phylloquinone—Dyspnoea—Zoledronate—osteoporosis	0.000311	0.00496	CcSEcCtD
Phylloquinone—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000303	0.00484	CcSEcCtD
Phylloquinone—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000299	0.00478	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL6—osteoporosis	0.000299	0.00368	CbGpPWpGaD
Phylloquinone—Pain—Zoledronate—osteoporosis	0.000298	0.00476	CcSEcCtD
Phylloquinone—Hypersensitivity—Risedronate—osteoporosis	0.000296	0.00472	CcSEcCtD
Phylloquinone—Pain—Conjugated Estrogens—osteoporosis	0.000287	0.00458	CcSEcCtD
Phylloquinone—Hypersensitivity—Pamidronate—osteoporosis	0.000281	0.00449	CcSEcCtD
Phylloquinone—Dizziness—Ethinyl Estradiol—osteoporosis	0.000272	0.00435	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—ACE—osteoporosis	0.000271	0.00333	CbGpPWpGaD
Phylloquinone—Anaphylactic shock—Estradiol—osteoporosis	0.000269	0.00429	CcSEcCtD
Phylloquinone—Dizziness—Risedronate—osteoporosis	0.000266	0.00424	CcSEcCtD
Phylloquinone—Hyperhidrosis—Estradiol—osteoporosis	0.00026	0.00414	CcSEcCtD
Phylloquinone—Hypersensitivity—Zoledronate—osteoporosis	0.000257	0.0041	CcSEcCtD
Phylloquinone—Dizziness—Pamidronate—osteoporosis	0.000252	0.00403	CcSEcCtD
Phylloquinone—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000247	0.00395	CcSEcCtD
Phylloquinone—Dyspnoea—Estradiol—osteoporosis	0.00024	0.00382	CcSEcCtD
Phylloquinone—Dizziness—Zoledronate—osteoporosis	0.000231	0.00368	CcSEcCtD
Phylloquinone—Pain—Estradiol—osteoporosis	0.00023	0.00367	CcSEcCtD
Phylloquinone—Dizziness—Conjugated Estrogens—osteoporosis	0.000222	0.00354	CcSEcCtD
Phylloquinone—Hypersensitivity—Estradiol—osteoporosis	0.000198	0.00316	CcSEcCtD
Phylloquinone—Dizziness—Estradiol—osteoporosis	0.000178	0.00283	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—LEP—osteoporosis	0.000168	0.00207	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—POMC—osteoporosis	0.000144	0.00178	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—IGF1—osteoporosis	0.000139	0.00171	CbGpPWpGaD
